Real‐world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO‐CLLEAR Study by the Czech CLL Study Group-Reference-Cited by-同舟云学术

Real‐world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO‐CLLEAR Study by the Czech CLL Study Group

Published:2020-06 Issue:4 Volume:38 Page:509-516
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Panovská Anna¹,Němcová Lucie¹,Nekvindová Lucie²,Špaček Martin³,Šimkovič Martin⁴,Papajík Tomáš⁵,Brejcha Martin⁶,Lysák Daniel⁷,Zuchnická Jana⁸,Novák Jan⁹,Starostka David¹⁰,Poul Hynek¹¹,Vrbacký Filip⁴,Vodárek Pavel⁴,Urbanová Renata⁵,Plevová Karla¹¹²,Pospíšilová Šárka¹¹²,Mašlejová Stanislava¹,Brychtová Yvona¹,Koriťáková Eva²,Smolej Lukáš⁴,Doubek Michael¹¹²^ORCID

Affiliation:

1. Department of Internal Medicine—Hematology and Oncology University Hospital and Masaryk University Brno Czech Republic

2. Institute of Biostatistics and Analyses, Ltd. Brno Czech Republic

3. 1st Department of Medicine—Department of Hematology, First Faculty of Medicine Charles University and General University Hospital in Prague Prague Czech Republic

4. 4th Department of Internal Medicine—Hematology University Hospital and Charles University Faculty of Medicine Hradec Králové Czech Republic

5. Department of Hematooncology University Hospital Olomouc Czech Republic

6. Oncology Center Nový Jičín Czech Republic

7. Department of Hematology and Oncology University Hospital Plzeň Czech Republic

8. Department of Hematology University Hospital Ostrava Czech Republic

9. Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady and Third Faculty of Medicine Charles University Prague Czech Republic

10. Department of Hematology Havirov Hospital and Polyclinic Havířov Czech Republic

11. Department of Hematology Hospital Pelhřimov Pelhřimov Czech Republic

12. Central European Institute of Technology Masaryk University Brno Czech Republic

Funder

F. Hoffmann-La Roche

Ministerstvo Zdravotnictví Ceské Republiky

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2744

Reference16 articles.

1. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment

2. National Cancer Institute [Website]. Surveillance epidemiology and end results cancer statistics review.2009.http://seer.cancer.gov/statfacts/html/clyl.html. Accessed September 5 2017.

3. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. Chronic Lymphocytic Leukemia and Focusing on Epidemiology and Management in Everyday Hematologic Practice: Recent Data From the Czech Leukemia Study Group for Life (CELL)

5. Chronic Lymphocytic Leukemia: A Review of Front-line Treatment Options, With a Focus on Elderly CLL Patients

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review;Frontiers in Oncology;2023-02-07

2. Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study;Frontiers in Oncology;2022-11-21

3. Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study;Blood Advances;2022-07-05

4. With great power comes great responsibility: Managing side effects of novel treatments in chronic lymphocytic leukemia (CLL);Canadian Hematology Today;2022-07-01

5. Safety and Efficacy of Bendamustine and Rituximab (BR) Regimen in Indian Chronic Lymphocytic Leukaemia Patients;Indian Journal of Hematology and Blood Transfusion;2022-05-27